---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-019881"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2024-06-11T23:59:59+00:00"
generated_at: "2026-06-01T05:04:39.198071+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Monopar expands NorthStar collaboration; secures Ac-225 supply & full MNPR-101 IP ownership

## Summary
- Long-term master supply agreement for actinium-225 from NorthStar for Monopar's development and commercial programs.
- Monopar acquires full ownership of MNPR-101 radiopharmaceutical platform and related jointly developed IP from NorthStar.
- Both companies share ownership of filed patent application on PCTA linker with Ac-225, showing superior binding vs. DOTA.
- NorthStar expected to be first commercial-scale producer of non-carrier added Ac-225 using electron accelerator technology.
- No financial terms disclosed; collaboration builds on NorthStar's Ac-225 manufacturing and Monopar's preclinical results.

## SEC filing metadata
- accession: 0001437749-24-019881
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2024-06-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774924019881/0001437749-24-019881-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774924019881/mnpr20240610_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-019881
- JSON: https://secwatch.observer/filing/0001437749-24-019881.json
- Plain text: https://secwatch.observer/filing/0001437749-24-019881.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.